Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Atrium Therapeutics, Inc.

NASDAQ: RNA · Life Sciences · 6 alerts · CIK 2093101

Atrium Therapeutics, Inc. stories on ALFA USA NewsRead the news →
Share price
$6.43Close, Nov 16
Market cap
$139M
Shares outstanding
21.57MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Atrium Therapeutics, Inc. filings on SEC EDGAR ↗

8:56 AM ET 8-K
Business Update

Atrium Therapeutics Business Update

Atrium Therapeutics announced the first patient has been dosed in its Phase 1/2 Corventis clinical trial evaluating ATR 1072 for the treatment of PRKAG2 syndrome. This represents the first interventional clinical trial for this rare genetic cardiomyopathy, with initial proof-of-concept data expected in the second half of 2027.

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.